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Abstract
The widespread usage of methylphenidate (MPH) in the pediatric population has received considerable attention due to its
potential effect on child development. For the first time a physiologically based pharmacokinetic (PBPK) model has been
developed in juvenile and adult humans and nonhuman primates to quantitatively evaluate species- and age-dependent
enantiomer specific pharmacokinetics of MPH and its primary metabolite ritalinic acid. The PBPK model was first calibrated
in adult humans using in vitro enzyme kinetic data of MPH enantiomers, together with plasma and urine pharmacokinetic
data with MPH in adult humans. Metabolism of MPH in the small intestine was assumed to account for the low oral
bioavailability of MPH. Due to lack of information, model development for children and juvenile and adult nonhuman
primates primarily relied on intra- and interspecies extrapolation using allometric scaling. The juvenile monkeys appear to
metabolize MPH more rapidly than adult monkeys and humans, both adults and children. Model prediction performance is
comparable between juvenile monkeys and children, with average root mean squared error values of 4.1 and 2.1, providing
scientific basis for interspecies extrapolation of toxicity findings. Model estimated human equivalent doses in children that
achieve similar internal dose metrics to those associated with pubertal delays in juvenile monkeys were found to be close to
the therapeutic doses of MPH used in pediatric patients. This computational analysis suggests that continued
pharmacovigilance assessment is prudent for the safe use of MPH.
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Introduction
Attention deficit hyperactivity disorder (ADHD) is one of the
most common childhood disorders and its frequent persistence
into adulthood has been increasingly recognized [1]. According to
a recent survey, the number of children in the U.S. diagnosed with
ADHD continues to increase. Nearly 2 million additional U.S.
children/adolescents aged 4 to 17 years were diagnosed with
ADHD in 2011, compared to 2003 [2]. The point prevalence of
ADHD is estimated to be 5–10% in children and about 3% in
adults [1]. Methylphenidate (MPH), a blocker of the monoamine
transporter that inhibits reuptake of dopamine and norepineph-
rine, remains a mainstay of treatment for ADHD [3]. Most MPH
formulations contain a racemic mixture (1:1) of the threo pair of
MPH isomers (d, l-threo MPH), which is more potent pharma-
cologically than its corresponding erythro pair [4–6]. In addition,
the d-threo-MPH (d-MPH) enantiomer exhibits a greater phar-
macological potency than the l-enantiomer, and there is no
evidence of interconversion between these two enantiomers [7–
10]. Starting in 1960s, conventional, immediate-release MPH
became the primary stimulant used to treat ADHD symptoms.
Due to its short-term action (typically only lasting for 4 hours), IR
MPH is typically given two to three times a day to cover normal
school and after-school hours [11]. However, under such a dosing
schedule, children may experience inattention during the trough in
MPH levels, e.g. during late morning classes. Other problems
associated with multiple dose regimens are compliance, confiden-
tiality, and drug security issues at school. Given the dosing
limitations of immediate-release MPH, several extended-release
MPH formulations with longer effective durations of action have
been introduced into the market [3,12,13].
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In humans, MPH is metabolized predominantly by hydrolysis
(de-esterification) to the pharmacologically inactive ritalinic acid
(RA), with pronounced enantioselectivity in favor of the l-
enantiomer [4,10,13–15] (Figure 1). Human carboxylesterase
(CES) 1A1 has been shown to be the major enzyme responsible
for the stereoselective hydrolysis of MPH [16]. In addition, other
minor metabolites produced through oxidation and subsequent
conjugation or hydrolysis, including the pharmacologically active
metabolite para-hydroxymethylphenidate [17], have also been
identified in humans [18]. Extensive first-pass metabolism of total
MPH (d-and l-MPH) results in low absolute oral bioavailability of
the racemic drug. In healthy adult humans, only 2268% and
563% of the d- and l-MPH, respectively, reach the systemic
circulation [4]. In children diagnosed with hyperactivity, the
systemic bioavailability of total MPH ranges from 11 to 52%, with
an average of 31616% [19]. The majority of MPH administered
orally or by intravenous (iv) injection is excreted in urine,
accounting for 80% [18] and 78–97% [20] of the administered
dose within 48 h and 96 h, respectively. Only 3% of the
administered MPH dose is recovered in feces over a 48 h period
[18]. The major metabolite of MPH identified in urine is the
hydrolytic metabolite RA, accounting for 80% of the total urinary
excretion, following both oral and iv administration, while
unmetabolized MPH accounted for less than 1% [13,18].
The metabolism and disposition of MPH has been investigated
in a variety of laboratory animals including rats, mice, and dogs
[18,21]. In contrast to humans, both microsomal oxidation and
hydrolysis are important metabolic pathways for rats, mice, and
dogs [18,21]. In monkeys, RA (hydrolysis) has been shown to be a
major metabolite of MPH [22,23] and the oral bioavailability for
total MPH was reported to be 22% in young monkeys [24].
Some health concerns exist for children and adults who are
treated chronically with MPH. In a pediatric study to evaluate
diurnal changes in salivary hormones of children taking psycho-
tropic medications, those taking MPH tablets exhibited diminished
diurnal rhythms of testosterone, while children taking extended-
release MPH tablets had significantly higher testosterone levels
[25]. In MPH toxicity studies in monkeys, juvenile male rhesus
monkeys exhibited transient delays in puberty, lower serum
testosterone levels, impaired testicular descent, and reduced
testicular volume [26]. In another study, increases in blood
testosterone levels were observed in peri-adolescent male rhesus
monkeys [27].
To extrapolate the MPH toxicity findings reported in juvenile
monkeys to children, a physiologically based pharmacokinetic
(PBPK) model was constructed for MPH and its major metabolite
RA for the first time. The model structure accounted for both the
d- and l- enantiomers of MPH and RA in adult and young
humans and non-human primates. The MPH PBPK model
provided a computational methodology to evaluate and compare
the pharmacokinetics of pharmacological doses of MPH in
children with MPH doses used in the toxicity studies with juvenile
rhesus monkeys. The metabolism and pharmacokinetics of MPH
in young and adult humans have been evaluated for both
immediate-release and extended-release MPH formulations. For
juvenile and adult rhesus monkeys experiments conducted at the
National Center for Toxicological Research (NCTR) in Jefferson,
AR, only an immediate-release MPH formulation was used.
Hence, to allow for cross-species comparison and extrapolation of
MPH internal doses, only data obtained after the administration of
immediate-release MPH are considered in the current manuscript.
Materials and Methods
Ethics Statement
All animal procedures were approved by the NCTR Institu-
tional Animal Care and Use Committee.
Key pharmacokinetic studies in humans
Given that d-MPH and l-MPH exhibit distinct pharmacokinetic
profiles [4,10,14,15] and pharmacological activities [7–10],
simultaneous PBPK model predictions of both enantiomers are
clinically relevant. Therefore, therapeutic drug monitoring studies
utilizing enantiospecific assays were preferentially selected for
human model development. In addition, pharmacokinetic studies
with parallel measurements of MPH and its major metabolite RA
concentrations were also considered important for tracking the
mass balance of MPH and the fraction of MPH metabolized by
the hydrolytic pathway. Pharmacokinetic data sets used for model
calibration and evaluation for healthy adult humans and children
with ADHD are briefly summarized below (Table S1 and Table
S2). MPH used in these studies is assumed to consist of a 1:1
racemic mixture of d- and l-enantiomers [4–6,13], unless the use
of d-MPH is indicated. In addition, unless specified otherwise,
MPH and RA concentrations mentioned hereinafter refer to total
(d- plus l-) MPH and total (d- plus l-) RA concentrations.
Pharmacokinetic data sets used to calibrate the adult human
model were from iv and oral dosing studies [4,24,28–33]. For iv
dosing, the first data set used to calibrate the model was time
course of plasma d- and l-MPH concentrations following a single
iv dose of 10 mg MPH in healthy adult men (n= 13) [4]. The
second iv study used to calibrate the model was urinary excretion
time course data for d- and l-RA in healthy adult men
administered a single iv dose of 10 mg MPH (n= 9) [28]. For
oral dosing, a total of six data sets were used for model calibration
[24,29–33], of which, three data sets provided time courses of
plasma d- and l-MPH concentrations in healthy adults following a
single oral dose of MPH at 0.3 mg/kg (n= 24) [29], 0.3 mg/kg
(n= 19) [30], and 40 mg (n= 21) [31]; the other three studies
reported time courses of plasma MPH and RA concentrations in
healthy adult men following a single oral dose of MPH at 20 mg
(n= 5) [32], 20 mg (n= 8) [33], and 0.15 and 0.3 mg/kg (n= 10)
[24].
Pharmacokinetic data sets used to evaluate the adult human
model were oral dosing studies [20,28,34–37]. The first kinetic
studies used for testing the model were time courses of plasma d-
MPH concentrations in healthy adults following a single oral dose
of 50 or 90 mg MPH (n=49) [34] and repeated oral doses of
30 mg MPH (n=28) [35]. The second kinetic studies used for
model evaluation were time courses of plasma MPH concentra-
tions in healthy adults given a single oral dose of 20 mg MPH
(n= 20) [36] and repeated oral doses of 5 mg MPH (n= 35), for
which plasma RA concentrations were also determined [37]. The
third kinetic studies used for model evaluation were urinary
excretion time courses in healthy adult men for d- and l-RA
following a single oral dose of 40 mg MPH (n= 9) [28] and for RA
after a single oral dose of 20 mg MPH (n= 3) [20]. Additional
plasma pharmacokinetic data sets in healthy adults administered
either a single oral dose or repeated oral doses of MPH or d-MPH
were also used for adult human model evaluation [38–43] (Text
S1).
For children, one study reported serum MPH kinetics in boys
administered 10–20 mg MPH intravenously (n = 6) [44] and
another study reported serum peak RA levels in boys administered
10–15 mg MPH intravenously (n = 5) [19]. However, attempts to
use these data sets for pediatric model development were not
PBPK Model for Methylphenidate
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successful. Systemic clearance of MPH for children in the study of
[44] is dramatically different from adult humans [4]. Hepatic
metabolic constants describing MPH hydrolysis by human
carboxylesterase 1 (hCES1) (see below for model description)
need to be increased to approximately 50 fold of adult values to
capture the rapid clearance of MPH observed for these children
[44] while maintaining the appropriate estimation of serum RA
levels [19]. Accordingly, the resultant scaled hepatic hydrolysis
rate (mg/h) in children is 22–36 fold of adult human values. This is
inconsistent with the finding that children show similar hepatic
expression and activity of hCES1 enzyme compared to adult
humans [45]. Further, plasma concentrations of MPH enantio-
mers following oral administration of 10 mg MPH in children
[7,46–51] are under estimated to a great extent using these large
hepatic metabolic constants derived from these two studies
[19,44], even if assuming a rapid oral uptake and no gut
metabolism. Eventually these two studies were excluded from
data sets used for model development and evaluation because of
their inconsistency with respect to several other MPH pharmaco-
kinetic data sets in children [7,46–51]. Hence, the pediatric MPH
model was developed using MPH pharmacokinetic data sets
following oral dosing in children [7,19,46]: of which, two studies
provided plasma concentration time courses of d- and l-MPH
following a single oral dose of 10 mg MPH in 5 boys with
attention deficit disorder (ADD) [46] and 9 boys with ADHD [7];
and in another study, Chan et al. [19] reported peak serum RA
levels in boys administered 10–15 mg MPH orally (n = 5).
Several additional pharmacokinetic data sets in children orally
administered MPH were used for model evaluation [47–51]. The
first data sets used for testing the model were plasma d-MPH
concentration time courses in 14 preschool (4–5 years) and 9
school-aged (6–8 years) children with ADHD administered a single
oral dose of 2.5–10 mg MPH [49] and in 31 boys with ADHD
given a single oral dose of 5–20 mg MPH [50]. The second data
sets used for model evaluation were plasma MPH concentration
time courses in boys with ADD administered a single oral dose of
MPH at 0.34 and 0.65 mg/kg (n= 14) [47], and in children with
ADHD given repeated oral doses of MPH at 5–15 mg (normalized
to a 5 mg dose, n = 14) [48] and 10–40 mg (normalized to a
20 mg dose, n = 14) [51].
Key pharmacokinetic studies in nonhuman primates
The monkey MPH pharmacokinetic study reported by Wargin
et al. [24] was used for model calibration. In this study, 5 young
monkeys, aged 2.5 years, were dosed intravenously with 3 mg/kg
of MPH and blood samples were collected over 9 hours [24].
Accordingly, MPH used for monkey studies is assumed to consist
of a 1:1 racemic mixture of d- and l-enantiomers [4–6,13] as well.
Unreported pharmacokinetic data collected from a chronic
MPH toxicity study at NCTR with juvenile rhesus monkeys
[22,23,26] were also used to calibrate the monkey MPH PBPK
model. The experimental design is briefly described below. In a
preliminary study conducted to determine the most appropriate
vehicle for MPH, 4 adult female rhesus monkeys (6.5–9.8 kg) were
dosed with 0.3 mg/kg of MPH (USP grade, Mallinckrodt, St.
Louis, MO) by oral bolus gavage (solution in Prang, Bio-Serv,
Frenchtown, NJ) and via iv administration. Blood samples were
collected at 13 time points after iv dosing and 9 time points after
oral dosing over a 24 h period and plasma levels of both MPH and
RA were determined by HPLC-MS/MS [52].
Based on plasma level data obtained from these studies in adult
monkeys, a chronic toxicity study was performed with MPH and
juvenile male rhesus monkeys [22,23,26]. Twenty male rhesus
monkeys, approximately 2.5 years old at the beginning of the
experiment (an age approximately equivalent to 7.5 year old boys,
estimated based on maximum life-span of 122 and 40 years in
humans and rhesus monkeys [53,54]), were treated orally with
MPH. The details of the study design and toxicity findings have
been published in Morris et al. [23] and Mattison et al. [26]. Each
lot of MPH (USP grade, Mallinckrodt, St. Louis, MO) was
examined for purity prior to use in the study. All lots were
determined to be structurally consistent with the NIST standard
for MPH, with purity $99.0%. MPH was dissolved in Prang (Bio-
Serv, Frenchtown, NJ), an oral rehydration solution commonly
used as a vehicle in non-human primate experiments. Test article
preparation occurred weekly and each dose preparation was
analyzed by HPLC-MS/MS [52] for dose accuracy. Only dose
preparations that were within 610% of the target dose were used.
The test subjects were dosed twice a day (with a 4 hour interval),
5 days a week (Monday to Friday) via an oral dosing syringe. Both
low dose (0.15 mg/kg of MPH, n= 10) and high doses (1.5 mg/kg
of MPH, n= 10) were increased to final doses of 2.5 and 12.5 mg/
kg [26]. These dose adjustments were required to achieve clinically
relevant pediatric blood concentrations of MPH (2–10 ng/mL)
[26,55]. During the chronic MPH toxicity study, blood samples
were collected after administration of MPH on a quarterly basis
for about a 1-year period. On the days of blood collection
(Monday to Thursday), the monkeys only received the first
(morning) dose of MPH and blood samples were collected at eight
time points from pre-dose to 24 h post-dose: samples were
collected from 1–4 monkeys per time point. The monkeys
underwent preliminary training for blood collection and were
not anesthetized during the pharmacokinetic experiments. Plasma
MPH and RA concentrations were determined for each monkey
using an HPLC-MS/MS method [52]. Measurements of plasma
MPH concentrations pre-dose and at 24 h post-dose were
excluded due to quantitation limitations. Kinetic profiles of
MPH and RA for each individual monkey were followed on the
same day of the week when quarterly blood sampling occurred
over the 1-year period.
Another nonhuman primate toxicity study with MPH [27], and
limited plasma measurements of MPH, were used for evaluation of
the monkey model. In this study, 8 male rhesus monkeys from
Johns Hopkins University, approximately 3–4 years old, weighing
3.1–10.2 kg, were orally dosed with MPH in Tang solution via a
15-min self-dosing procedure, twice a day (at 0900 and 1200
hours), 7 days a week [27]. The average consumed MPH doses
were 10.7 (8.89–13.1) and 16.5 (15.5–18.7) mg/kg, with the target
intake determined to be 12–16 mg/kg, which produced the
therapeutic blood levels of 15–25 ng/ml [27]. Blood sampling
occurred periodically at 1000 and 1300 hours, and MPH plasma
concentrations were quantified using a GC-MS method.
PBPK model for MPH and RA
Two duplicate 8-compartment PBPK models for d- and l-MPH
enantiomers (plasma, fat, brain, richly perfused, slowly perfused,
gonads, heart, and liver) were constructed for children and adult
humans as well as juvenile and adult rhesus monkeys. Competitive
metabolic inhibition of each MPH enantiomer was described in
the liver giving rise to formation of the primary metabolites, d- and
l- ritalinic acid. Ritalinic acid was described using one compart-
ment for each enantiomer (Figure 2). The selection of compart-
ments for MPH was based on the metabolism and disposition as
well as the potential target tissues of MPH (e.g. gonads, brain, and
heart) [12,26,56]. The d- and l-RA enantiomers lack pharmaco-
logical activity [57] and were simply described without tissue
compartments. The decay of MPH from systemic circulation and
tissues occurred at a similar rate [58–60]. As such, distribution of
PBPK Model for Methylphenidate
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MPH to the tissues was assumed to be flow limited in the current
model. The simulations were performed using acsIXtreme, version
3.0.2.1 (The Aegis Technologies Group, Inc., Huntsville, AL).
Tissue to plasma partition coefficients. Tissue-to-plasma
partition coefficients for MPH were estimated using a mechanistic
model [61] based on tissue composition and compound specific
parameters. A single pKa value of 9.51 (moderate base), a logP
value of 2.31, and a logD value of 0.24 at pH 7.4 were predicted
for MPH using the ACD Lab Solubility Suite (Advanced
Chemistry Development, Inc., Toronto, Ontario, Canada). These
properties were then used to estimate tissue and plasma partition
coefficient values. Due to lack of available information, partition
coefficients derived in one animal species have been applied for
other animal models as well as humans, and vice versa [62,63]. As
such, in the current model, tissue-plasma partition coefficient
values for liver, brain, and heart were determined based on
monkey tissue composition, while those for fat and gonads were set
to the values estimated in rats. Tissue-to-plasma partition
coefficients for richly perfused and slowly perfused tissues were
set to the values of the liver and the muscle estimated in monkeys
(Table 1). The estimated tissue-to-plasma partition coefficients
were generally consistent with those derived from the terminal
phase of plasma and tissue pharmacokinetics studies in rats [58–
60].
Figure 1. Metabolic pathways of methylphenidate in humans.
doi:10.1371/journal.pone.0106101.g001
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Physiological model parameters. The physiological model
parameters PBPK for adult humans were derived from the
literature (Table 2). For children, volume of tissues as a function of
age, except for the fat, were estimated using the equations
developed by Haddad et al. [64]. The volume for the fat was
predicted using a TABLE function based on the calculated adipose
tissue volumes of 3.68, 6.25, and 11.49 L for children 6, 10, and
14 yrs of age, respectively, for which lipid contents of all other
tissues were excluded [65]. Changes in plasma volumes during
growth were predicted as a function of body weight [66]. The
reported cardiac output (QC, L/h) values in children, aged 0.5 to
15 years [67,68], were assembled and fitted with regression
equations to describe the relationship between QC (L/h) and age
(year) in males and females:
QC(male)~
79:7195z19:2943|age{0:5954|age2z0:0501|age3
ð1aÞ
QC(female)~
78:5177z6:9146|agez2:6301|age2{0:1122|age3
ð1bÞ
Liver blood flow rates (Qliver, L/h) at different ages were
predicted using a TABLE function based on the reported average
liver blood flow rates of 325, 665, and 915 ml/min for children
aged 4–8, 9–12, and 13–15 years, respectively [69]. Blood flow
rates (L/h) to the brain (Qbrain) were estimated using the
following best fit equation as a function of age (0.5 to 15 yrs)
derived from the reported values [67]:
Qbrain(male)~
25:2643z14:5166|age{1:6861|age2z0:0537|age3
ð2aÞ
Qbrain(female)~
24:0103z12:9428|age{1:4845|age2z0:0462|age3
ð2bÞ
Because of the lack of information on age-specific blood blows
to the heart, fat, and gonads, the same percentages of cardiac
output that were reported for adults were adopted for children.
Physiological PBPK model parameters for adult and juvenile
rhesus monkeys were derived from the literature for adult
monkeys, with the exception of gonads, which were taken from
the human literature (Table 2).
Model Development: Adult Humans
MPH: hepatic metabolism. In adult human livers, the
majority (approximately 80%) of MPH is metabolized by
hydrolysis resulting in the formation of RA [18], while the
remaining is subject to oxidation [13,18]. The stereoselective
hydrolysis (Rmet_liver, mg/h) of d- and l-MPH was described
using a Michaelis-Menten equation representing the competitive
binding to the hCES1A1 enzyme between d- and l-MPH [16,29]:
Rmet liver~
V max liver|CVliver
Kmliver|(1z
CVliverinhibitor
Kmliverinhibitor
)zCVliver
ð3Þ
The Michaelis constants for d- and l-MPH (Kmliverd and
Kmliverl, mg/L) were set equal to the reported Km values of
27,600 and 10,172 mg/L, experimentally determined using the
recombinant human CES1A1 enzyme [16] (Table 3). CVliver is
the venous plasma concentration leaving the liver for one isomer
(CVliverd and CVliverl, mg/L) and CVliverinhibitor is the venous
plasma concentration leaving the liver for the inhibiting isomer
(CVliverl and CVliverd, mg/L). Kmliverinhibitor represents the
dissociation constant for the inhibiting isomer, set to the Kmliver
value of that isomer (Kmliverl and Kmliverd, mg/L). Vmaxliver
(mg/h) is a scaled maximum hepatic reaction velocity, described as
the product of the maximum hepatic reaction velocity constant
(VmaxliverdC and VmaxliverlC, mg/h/kg0.75, for d- and l-MPH)
and the body weight (BW)0.75. VmaxliverdC and VmaxliverlC
Figure 2. Schematic depicting the PBPK model for MPH and its primary metabolite RA. Two identical 8-compartment models were
constructed for d- and l-MPH and two identical one-compartment models were built for d- and l-RA. MPH was given intravenously or orally. In
humans, MPH is metabolized predominantly by hydrolysis to pharmacologically inactive RA, which is subsequently excreted into urine.
doi:10.1371/journal.pone.0106101.g002
Table 1. Estimated tissue-plasma distribution coefficients for MPH.
Tissues Partition coefficients (tissue/plasma)
Fat (Pfat) 1.79
Brain (Pbrain) 6.07
Richly perfused (Prich) 5.66
Slowly perfused (Pslow) 2.47
Gonads (Pgonads) 3.12
Heart (Pheart) 2.19
Liver (Pliver) 5.66
doi:10.1371/journal.pone.0106101.t001
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(mg/h/kg0.75) were initially derived from the calculated in vitro
maximal velocity of 38,496 and 78,111 ng/h/mg protein, which
were obtained based on the reported in vitro catalytic constant
values (Kcat, 0.165 min21 and 0.335 min21 for d- and l-MPH)
using the recombinant human CES1A1 enzyme [16]. The in-vitro
in-vivo extrapolations (IVIVE) were performed by accounting for
microsomal protein content of the liver (39.19 mg microsomal
protein/g liver [70]) and model predicted average liver weight
(2.06 kg) for healthy men 18–30 years old [4], and estimated body
weight of 74.8–84.02 kg [38]. A relative activity factor of 0.22,
determined as the ratios of the imidapril hydrolase activity in
human liver microsomes to the value for recombinant human
CES1A1 enzyme [71], was considered to bridge the gap between
the recombinant enzyme and native liver microsomes. Optimiza-
tion of IVIVE derived VmaxliverdC and VmaxliverlC values was
attempted using the NelderMead algorithm by simultaneous fitting
to plasma concentration time courses of d- and l-MPH following iv
dosing of 10 mg MPH in healthy adult men over a period of 16 h
[4]. A convergence of values for VmaxliverdC and VmaxliverlC
could not be achieved. Hence, the derived initial VmaxliverC
values for d- and l-MPH were eventually adjusted manually
(1.5 fold) to attain the best agreement between prediction and
observed plasma d- and l-MPH concentrations (Table S1).
The oxidation metabolic pathways for the MPH enantiomers in
the liver were described using clearance terms (KmetdC and
KmetlC, L/h/kg0.75). This metabolic pathway for each enantio-
mer was constrained to yield an upper bound equal to 20% of the
total dose metabolized in the liver [18]. The enzymes responsible
for the hepatic oxidation of MPH have not yet been identified.
CYP2D6 is known not to be involved [72].
MPH: Oral uptake and gastrointestinal (GI) tract
metabolism. The use of the hepatic metabolic constants
derived from iv dosing of adult humans consistently overestimated
the plasma levels of MPH following oral administration, even with
a small first order oral uptake constant. The metabolism of MPH
in the GI tract by hydrolysis and oxidation was introduced into the
human PBPK MPH model to achieve better predictions of
observed plasma MPH concentrations following oral administra-
tion [24,29–33]. The rationales for the inclusion of GI tract
metabolism are as follows.
Though the predominant human CES1 enzyme identified for
the hydrolysis of MPH was found primarily in human livers,
expression of CES1 is also present in the human GI tract as
identified by Northern blots [73,74]. In addition, hydrolysis of
flurbiprofen derivatives (flurbiprofen hydroxyethyl ester and
hydroxypropyl ester), which are excellent substrates for hCES1
but not for hCES2, has been reported in human small intestine
microsomes [75]. Other interesting observations suggest that the
pharmacokinetics of the orally administered MPH is much less
straightforward than iv administration. Higher plasma levels of d-
MPH compared to l-MPH were observed immediately after oral
administration (0.5 h), but not apparent until 1.5 h after iv
administration [4]. Also, a distortion of the enantiomeric ratio for
RA (l..d) was observed in both human plasma and urine
samples in the first 2 h after oral but not iv administration [28,58].
Such route-dependent discrepancies found in the first 2 hours after
dosing suggested the potential enantioselective presystemic
metabolism of orally administered MPH in the GI tract.
Expression of CYP enzymes has also been reported in human
small intestines [76], although the enzymes responsible for the
oxidation of MPH have not been identified [72,77]. As such,
metabolism of MPH in the GI tract by hydrolysis and oxidation
was considered in the model, which was crucial to improving
model performance.
Following oral administration of MPH, gastric emptying of d-
and l-MPH into the small intestine was described using first order
Table 2. Physiological model parameters.
Parameters Adult Humans Children Monkeyse References
Body weight, BW (kg) Study specific Study specific Study specific Experimental data or [105]H [106]C
Cardiac output, QCC (L/h/kg0.75) 15.87 Calculated using Eq.1 18.96 [63]H,M
Blood flows (fraction of cardiac output)
Fat (QFC) 0.053/0.091a 0.053/0.091b 0.02 [68]H [80]M
Liver (QLC) 0.24 Calculated 0.194 [63]H [65]C [63]M
Brain (QBC) 0.11 Calculated using Eq.2 0.07 [107]H [80]M
Heart(QHC) 0.038/0.047a 0.038/0.047b 0.055 [67]H [80]M
Gonads (QGC) 0.00054/0.00022a 0.00054/0.00022b 0.00054/0.00022b [68]H
Richly perfused (QRC) 0.76-QLC-QGC-QBC 0.76-QLC-QGC-QBC 0.76-QLC-QGC-QBC
Slowly perfused (QSC) 0.24-QFC-QHC 0.24-QFC-QHC 0.24-QFC-QHC
Tissue volumes (fraction of body weight)
Plasma(VPC) 0.0435 Calculated 0.0627 [63]H [66]C [63]M
Fat (VFC) 0.213/0.327a Calculated 0.179/0.199a [63]H [65]C [108]M
Liver (VLC) 0.026 Calculated 0.03 [107]H [64]C [80]M
Brain (VBC) 0.02 Calculated 0.018 [107]H [64]C [80]M
Heart(VHC) 0.0045/0.0042a Calculated 0.0037 [67]H [64]C [80]M
Gonads (VGC) 0.0007/0.0027a Calculated 0.0007/0.0027b [63]H [64]C
Richly perfused (VRC) 0.33-VLC-VPC-VGC-VBC 0.33-VLC-VPC-VGC-VBC 0.33-VLC-VPC-VGC-VBC
Slowly perfused (VSC) 0.60-VFC-VHC 0.60-VFC-VHC 0.60-VFC-VHC
amale/female; bset to adult human values; efor both adult and juvenile monkeys; Hadult humans; Cchildren; Mmonkeys.
doi:10.1371/journal.pone.0106101.t002
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gastric emptying constants (GEdC and GElC, 1/h/kg20.25) set to
a value of 3.5 1/h/kg20.25 [63,78]. The majority (80%) of orally
administered MPH was excreted in urine. RA accounted for 80%
of total urinary metabolites, and feces accounted for 3.3% [18].
MPH emptied from the stomach lumen into the small intestine
lumen was assumed to be immediately available within enter-
ocytes, where MPH is either rapidly absorbed into the portal blood
supply [13] or metabolized in the GI tract as discussed above. The
oral uptake of d- and l-MPH was described as a first order process
(K3dC and K3lC, 1/h/kg20.25), with no evidence for the
stereospecific absorption [16]. To account for the metabolic
degradation of d- and l-MPH in the gut, first-order terms (K5dC
and K5lC, 1/h/kg0.75) were employed, of which, a fraction
(F = 0.80, 80%) was assumed to undergo hydrolysis to form RA,
and be immediately absorbed into the systemic circulation. The
remaining fraction (1-F) was assumed subject to oxidation.
Optimized oral uptake constants (K3dC and K3lC, 1/h/kg20.25)
and metabolism constants (K5dC and K5lC, 1/h/kg0.75) for d-
and l-MPH were obtained by simultaneous fitting to plasma
concentrations of d- and l-MPH in adult humans orally dosed with
MPH at 0.3 mg/kg [29,30] and 40 mg [31], as well as plasma
concentrations of MPH and RA in adult men orally dosed with
MPH at 20 mg [32,33] and 0.15 and 0.3 mg/kg [24] (Table S1).
Optimization was carried out using the NelderMead algorithm.
RA: formation, distribution and systemic
clearance. The rate of MPH hydrolysis in the liver and the
GI tract was set equal to the rate of RA formation. Given that RA
is highly soluble in the aqueous medium [79], the volume of
distribution for RA was set to the value of total body water volume
(0.6 L/kg) in adult humans [80]. Optimized systemic clearance
terms for d- and l-RA (Ku_RAdC and Ku_RAlC, L/h/kg0.75)
were obtained by simultaneous fitting to the urinary excretion of d-
and l-RA over a period of 16 h after iv dosing of 10 mg MPH in
healthy adult men [28] (Table S1). Optimization was performed
using the NelderMead algorithm.
Model Development: Children
Stereoselective metabolism of MPH (l..d) has been docu-
mented in children [7,46]. Also the expression and activity of
hCES1 toward MPH in liver S9 fractions did not differ between
children (aged 6–18 years old) and the pooled adult human
samples [45]. Thus, the maximum velocity constants for hepatic
metabolism (hydrolysis) of l- and d- MPH (VmaxliverdC and
VmaxliverlC, mg/h/kg0.75) in children were set to the adult values.
With no information to assume otherwise, hepatic oxidation of l-
and d-MPH was also assumed to occur in children. Though the
predominant enzymes responsible for the oxidation of MPH have
not yet been identified, studies have demonstrated that the CPY3A
subfamily is the most important subfamily among the total P450
enzymes responsible for the biotransformation of drugs in the
human liver, with CYP3A4 as the most abundant isoform [81,82].
As such, the age-dependent oxidation of MPH in the liver was
assumed to be represented by the ontogeny of CYP3A4 enzymes.
Hepatic RNA and protein contents of CYP3A4 as well as its
activity, characterized by 6b hydroxylation of testosterone,
reached adult values after 1 year of age [83]. For this reason,
the clearance terms describing the metabolism of l- and d-MPH
via oxidation (KmetdC and KmetlC, L/h/kg0.75) in the liver of
children were assumed to be the same as adults. Since no data are
available to describe the age-dependent oral uptake and metab-
olism of MPH in the gut, model parameters specific for oral dosing
describing oral uptake (K3dC and K3lC, 1/h/kg20.25) and gut
metabolism (K5dC and K5lC, 1/h/kg0.75) for children were
assumed to be the same as adult humans.
Scaling of adult MPH-specific model parameters performed
well for the prediction of plasma d-MPH levels, but consistently
underestimated plasma l-MPH levels in boys administered 10 mg
MPH orally [7,46], even with a large oral uptake rate constant for
l-MPH, suggesting that systemic clearance of l-MPH is slower in
children compared with adults after oral dosing. Optimization of
oral uptake and hepatic and gut metabolic parameters for MPH
enantiomers was conducted using the NelderMead algorithm by
simultaneous fitting to the plasma concentration time courses of d-
and l-MPH in these children [7,46], but consistent convergence of
parameter values could not be achieved. Thus, with other MPH-
specific parameters fixed to adult values, the first order constant
(K5lC, 1/h/kg0.75) describing gut metabolism for l-MPH was
decreased by approximately 14 fold to achieve better agreement
between model predictions and observed plasma concentration
time courses of l-MPH in these children [7,46] (Table S2).
The scaled clearance terms representing urinary excretion of l-
and d-RA (Ku_RAdC and Ku_RAlC, L/h/kg0.75) were set to the
adult values because of a lack of the time course RA concentra-
tions in plasma or urine of children. The volume of distribution for
RA was set to the body water volume of 0.572 L/kg in children
[84,85].
As a consequence of uncertainty in model parameter specificity,
this MPH PBPK model is fit for purpose. That is, model
parameters were fitted to provide agreement between observation
and prediction; other factors may be important, but are unknown
and not described in the model.
Model Development: Adult Monkeys
Due to the lack of experimental data to determine model
parameters in adult monkeys, the development of the monkey
PBPK model relied primarily on cross species extrapolation using
allometric scaling, as demonstrated in other PBPK models [62,63].
The model parameters for the adult human intravenously dosed
with MPH were used for the adult monkey intravenously dosed
with 0.3 mg/kg MPH (NCTR data). The volume of distribution
(VbodyC, L/kg) for RA was set to the total body water volume of
the adult monkey (0.693 L/kg) [80]. Adult human values for
parameters describing hepatic hydrolysis (VmaxliverdC and
VmaxliverlC, mg/h/kg0.75) and oxidation (KmetdC and KmetlC,
L/h/kg0.75) were used to describe plasma MPH concentration
time course in adult monkeys. Model parameters (Ku_RAdC and
Ku_RAlC, L/h/kg0.75) representing the systemic excretion of l-
and d-RA in adult monkeys were assumed to be the same as adult
humans.
Describing the kinetics of MPH after oral administration of
MPH in the adult monkey was not possible using adult human
model parameters describing oral uptake and adult monkey model
parameters derived from intravenous dosing of the adult monkey
with MPH. To improve predictions, the first order constants
describing the gut metabolism of d- and l-MPH (K5dC and K5lC,
1/h/kg0.75) were increased proportionally by 25 fold to visually fit
the plasma MPH concentrations from 1 to 8 h (clearance phase)
following a single oral dose of 0.3 mg/kg MPH in adult monkeys
(NCTR data). The rationale for this re-parameterization was
based on reports of more abundant intestinal expression of the
CES1 enzyme [75,86,87] in monkeys than humans and more
rapid hydrolysis of the CES1 substrates flurbiprofen derivatives (2
to 55 fold) [75] in monkey small intestines than humans.
Model Development: Young Monkeys
Because of the lack of information on MPH disposition in young
monkeys, the calibrated adult monkey model was extrapolated to
describe MPH kinetics in young monkeys, as other PBPK models
PBPK Model for Methylphenidate
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did [63,88]. In sharp contrast to adult monkeys, plasma MPH was
cleared more rapidly in young monkeys following iv administra-
tion [24]. To account for the observed rapid clearance of MPH in
young monkeys, both maximum hepatic reaction velocity
(VmaxliverdC and VmaxliverdC, mg/h/kg0.75) describing the
hydrolysis and the clearance term (KmetdC and KmetlC, L/h/
kg0.75) describing the oxidation in the liver derived from the adult
monkey model were simultaneously increased by 10- and 100-fold
to fit the plasma concentrations of MPH and RA following a single
iv dose of 3 mg/kg MPH in young monkeys [24]. Due to the lack
of information on urinary excretion of RA in young monkeys,
parameters describing urinary excretion (Ku_RAdC and Ku_R-
AlC, L/h/kg0.75) and volume of distribution (VbodyC, L/kg) for
young monkeys were set to adult monkeys values.
With hepatic metabolic constants for MPH and parameters
describing systemic distribution and clearance for RA determined
by iv dosing, plasma concentration time courses of MPH and RA
after repeated oral doses of 2.5 and 12.5 mg/kg of MPH in
juvenile monkeys (NCTR study) were predicted using gastric
emptying (GEdC and GElC, 1/h/kg20.25) and oral uptake (K3dC
and K3lC, 1/h/kg20.25) parameters derived from the adult
monkey model. The metabolism of MPH in the gut was not
considered necessary in young monkeys with respect to maintain-
ing reasonable prediction of time course kinetics of MPH and RA
in plasma. Research is needed to fully understand the metabolic
pathways of MPH in the liver and the GI tract for both adult and
young monkeys.
Assessment of Model Performance
Because of the concern for children only the juvenile monkey
and child MPH models were evaluated for their ability to predict
measured plasma pharmacokinetic data sets for MPH and d- and
l-MPH following oral administration of immediate-release MPH.
To access model performance, the Root Mean Squared Error
(RMSE) was calculated for data sets in the juvenile monkey
reported in this paper (NCTR data) and from Johns Hopkins
University [27] and for pediatric data sets reported by [7,46–51].
Model performance was calculated as following:
RMSE~
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
PN
1
(predicted{observed)2
N
vuuut
ð4Þ
where predicted is the model predicted plasma concentration and
observed is the reported plasma concentration. N represents
number of predictions and observations.
Interspecies Extrapolation (Monkey to Human)
Juvenile male rhesus monkeys, 5 years of age, experienced a
temporary decrease in circulating testosterone levels after chronic
oral exposure to 2.5 mg/kg MPH and for 12.5 mg/kg MPH, a
decrease in circulating testosterone levels along with impaired
testicular descent, and reduced testicular volume [26]. Boys are
more frequently diagnosed with ADHD than girls [89]. MPH is
approved by the FDA for use in patients 6 years of age and older
[13]. Given that the juvenile monkey toxicity data was in males,
the developmental toxicity of MPH was extrapolated from male
juvenile monkeys to boys between approximately 6 and 15 years of
age. The model performance (RMSE) for the 12.5 mg/kg juvenile
monkey dose group was judged inadequate for model predictions
in humans (see Results).
PBPK derived oral human equivalent doses (HEDs) were only
derived for the 2.5 mg/kg MPH juvenile monkey dose group.
MPH HED values were calculated for the dosimetrics, maximum
plasma concentration (Cmax, ng/mL) and daily area under the
plasma MPH concentration curve (daily AUC, ng/mL*h per day).
Preliminary simulations revealed no plasma accumulation of MPH
in juvenile monkeys following a child’s therapeutic dosing
schedule; while for children, a slight accumulation of plasma
MPH levels was noticed with periodicity reached within 3 days.
Thus, repeated daily oral dosing of MPH was simulated for 3–
7 days to ensure steady state of MPH for both juvenile monkeys
and children. Briefly, for juvenile monkeys, a one-week exposure
for oral ingestion of MPH (2.5 mg/kg) occurred twice with a 4-h
interval/day, 5 days a week, a dosing schedule utilized in the
juvenile monkey toxicity study with MPH [26]. The dose metrics,
Cmax and daily AUC calculated as the total AUC obtained from
1 week divided by 7 days (referred to as adjusted daily AUC, see
Table S3), were recorded for MPH. Then simulations for children
with repeated oral dosing of MPH twice a day, 7 days a week, with
doses 4 h apart, were conducted with varying doses of MPH. The
doses producing the equivalent internal dosimetrics (Cmax and
daily AUC) of MPH at steady state (from day 4 to day 7) for
children as those derived in the juvenile monkeys were determined
as MPH HEDs.
In addition, model-predicted internal dose metrics (Cmax and
daily AUC) in boys 6 and 15 years of age administered clinically
recommended doses by the American Academy of Pediatrics
(AAP) (0.3–0.8 mg/kg twice daily, taken 4 h apart) [90] for 1 week
were compared with those obtained in juvenile rhesus monkeys
experiencing delayed puberty as described above.
PBPK model code is contained in supplementary data (Text S2
and Text S3) and m files are available upon request.
Sensitivity analysis
A time course local sensitivity analysis was implemented to
assess the influence of parameter perturbations on model
predictions of total MPH and d-MPH plasma concentrations over
a 24-h period. A single oral dose of MPH (0.3 mg/kg) was
simulated in both young and adult humans and monkeys.
Normalized sensitivity coefficients (NSCs) were calculated using
the partial derivatives of model output with respect to model
parameters using the forward difference method, and normalized
by both model output and model parameter [91]:
NSC~
DO
O
|
P
DP
ð5Þ
where O is the model output (i.e. plasma concentration of total
MPH or d-MPH), DO is the change in the model output, P is the
value of the model parameter, and DP is the change in the
parameter value. Model parameters were individually increased by
1% of their original values with all the other parameters held
constant, except that simultaneous adjustment was conducted
when evaluating the volumes and blood flow rates for slowly and
richly perfused compartments to ensure mass balance. A positive
NSC indicates a direct association between the model output and
the corresponding parameter, while a negative NSC suggests the
model output is inversely correlated with the specific parameter.
Parameters with absolute NSC values greater than 0.1 were
assumed to be sensitive.
Results
Model Calibration: Adult Humans
For adult humans, enantioselective hydrolysis of d- and l-MPH
in the liver was described using a Michaelis-Menten equation (Eq.
PBPK Model for Methylphenidate
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3). The Michaelis affinity constants, Kmliverd and Kmliverl, were
set to values of 27, 600 and 10, 172 mg/L (Table 3), determined
using the recombinant human CES1A1 enzyme [16]. The
maximum hepatic reaction velocities, VmaxliverdC and Vmaxli-
verlC, were slightly adjusted from their initial IVIVE derived
values of 25,760 and 52, 270 mg/h/kg0.75 [16] to 38,000 and
90,000 mg/h/kg0.75 (Table 3) to get the best fit of plasma d- and l-
MPH concentration profiles over a period of 16 h in healthy adult
men (n= 13) following a single iv dose of 10 mg MPH [4] (Table
S1). In conjunction with these parameters describing hepatic
hydrolysis, hepatic oxidation of d- and l-MPH was described using
clearance terms, KmetdC and KmetlC, of 0.7 L/h/kg0.75 to
ensure approximately 20% of total hepatic metabolism occurs via
oxidation [18]. With these hepatic metabolic parameters, plasma
levels of d- and l-MPH in healthy adult men following a single iv
dose of 10 mg MPH [4] were modestly under predicted in the first
2 hours after dosing, and for the remaining 14 hours model
predictions agreed with observations (Figure 3A).
With model parameters describing hepatic hydrolysis (Vmaxli-
verdC and VmaxliverlC) and oxidation (KmetdC and KmetlC) of
d- and l-MPH resolved for adult humans, parameters representing
systemic distribution (VbodyC) and clearance (Ku_RAdC and
Ku_RAlC) of RA enantiomers were established. For d- and l-RA,
because of their high water solubility [79], the volume of
distribution (VbodyC) was set to a value of 0.6 L/kg equal to
the total body water volume in adult humans [80]. Subsequently,
the systemic clearance terms for d- and l-RA (Ku_RAdC and
Ku_RAlC, 0.305 and 0.168 L/h/kg0.75, Table 3) were deter-
mined by an optimization algorithm using urinary excretion data
of RA enantiomers collected over a period of 16 h in adult men
after a single iv administration of 10 mg MPH (n= 9) [28] (Table
S1). The calibrated model accurately reproduced the time course
of urinary excretion profiles of d- and l-RA [28] (Figure 3B).
With enantiospecific model parameters describing hepatic
hydrolysis (VmaxliverdC and VmaxliverdC) and oxidation
(KmetdC and KmetlC) of d- and l-MPH as well as systemic
distribution (VbodyC) and clearance (Ku_RAdC and Ku_RAlC)
of d- and l-RA established for iv dosing in adult humans, model
parameters specific for oral dosing of MPH representing oral
uptake and gut metabolism were determined (Table 3). The
gastric emptying first order constants for d- and l-MPH (GEdC
and GElC) were set to the same value of 3.5 1/h/kg20.25 [63,78].
As discussed in the Methods, MPH emptied from the stomach
lumen into the small intestine lumen was assumed to be
immediately taken up by enterocytes. Within enterocytes, MPH
is either rapidly absorbed into the portal blood supply [13] or
metabolized in the GI tract, of which a fraction (F, 80%) was
assumed to undergo hydrolysis to form RA and immediately be
absorbed into the system. Optimization of oral uptake (K3dC and
K3lC) and gut metabolism (K5dC and K5lC) constants was
undertaken by seeking agreement with plasma concentration time
courses of d- and l-MPH as well as MPH and RA in healthy adult
humans orally dosed with MPH [24,29–33] (Table S1), of which,
time courses of plasma d- and l-MPH kinetics were collected in
adult humans following a single oral dose of MPH at 0.3 mg/kg
(n = 24) (Figure 4A) [29], 0.3 mg/kg (n= 19) (Figure 4B) [30], and
40 mg (n = 21) (Figure 4C) [31] over a period of time up to 18 h;
and time courses of plasma MPH and RA kinetics were collected
in adult men following a single oral dose of MPH at 20 mg (n= 5)
(Figure 5A) [32], 20 mg (n= 8) (Figure 5B) [33], and 0.3 (n = 10)
(Figure 5C) and 0.15 mg/kg (n= 5) (Figure 5D) [24] over a period
of time up to 24 h. Optimized oral uptake constants (K3dC and
K3lC) with values of 1.293 and 1.2931/h/kg20.25 and gut
metabolism terms (K5dC and K5lC) with values of 0.042 and
1.426 1/h/kg20.25 (Table 3) along with other MPH-specific model
parameters in general provided a good prediction of these
measured d-MPH (Figures 4A–C) [29–31] and MPH (Figur-
es 5A–D) [24,32,33] plasma kinetics with some exceptions: as
shown in Figure 4C, the model overestimated plasma d-MPH
level at 18 h by approximately 4 fold [31]; for plasma MPH levels,
observations at 8 h for the studies of [32] (Figure 5A) and [24]
(Figure 5D) were overestimated by 2–3 fold. Together with
systemic distribution (VbodyC) and clearance (Ku_RAdC and
Ku_RAlC) terms for d- and l-RA determined from iv dosing in
adult humans, model predicted and measured plasma RA
concentrations [24,32,33] (Figures 5A–D) were in general good
agreement with the exception of one study [32], for which the
model captured the time course of plasma RA concentrations for
the first 2 hours post-dose, but slightly overpredicted observations
for the remaining time points within 2–4 fold (Figure 5A).
Model Calibration: Children
As described in the Methods, hepatic metabolic parameters
representing hydrolysis (VmaxliverdC and VmaxliverlC, 38,000
and 90,000 mg/h/kg0.75) and oxidation (KmetdC and KmetlC,
0.7 and 0.7 L/h/kg0.75) of d- and l-MPH for children were set to
adult values given that children display similar expression and
activity of CES1 [45] and CYP3A4 [83] enzymes in the liver
compared with adults. With no information to assume otherwise,
MPH-specific model parameters representing oral uptake and gut
metabolism (Table 3) were set to adult human values, except that
the gut metabolism constant for l-MPH (K5lC) was visually
adjusted from adult value of 1.426 to 0.1 1/h/kg0.75 to achieve a
better fit to plasma concentration time course data of l-MPH over
a period of up to 8 h in children following oral dose of 10 mg
MPH [7,46].
With the constant of K5lC recalibrated and other MPH-specific
model parameters set to adult human values (Table 3), model
predictions of plasma d- and l-MPH concentrations in boys with
ADHD (n= 9, Figure 6A) and ADD (n= 5, Figure 6B) orally
dosed with 10 mg MPH in general tracked experimental data
except that in the study of [46] systemic clearance of d-MPH after
2 h was slightly faster than the model forecasted within a factor of
2–3 (Figure 6B). With all RA-specific model parameter values
previously calibrated from the adult human model (Table 3),
model estimated serum concentrations of RA for boys adminis-
tered 10–15 mg MPH orally were in general consistent with the
reported values (Table 4) [19].
Model Calibration: Adult Monkeys
Model parameters describing hepatic hydrolysis (VmaxliverdC
and VmaxliverlC, 38,000 and 90,000 mg/h/kg0.75) and hepatic
oxidation (KmetdC and KmetlC, 0.7 and 0.7 L/h/kg0.75) of d-
and l-MPH for adult monkeys were set to adult human values
(Table 3) given that monkeys exhibit similar hepatic CES1 [75]
and P450 [92] activities as humans. Model simulations in general
tracked the behavior of MPH in plasma over a period of 24 h for
adult monkeys (n = 4) following iv administration of 0.3 mg/kg
MPH (NCTR data), except that the measured levels were slightly
overestimated at 6 h and 8 h, within a factor of 3 (Figure 7A). One
plasma sample at 6 h and two other plasma samples at 24 h
contained non-quantifiable levels of MPH (0.1 ng/mL limit of
quantification, LOQ) [52]. Due to lack of information, values of
Ku_RAdC and Ku_RAlC (0.305 and 0.168 L/h/kg0.75) repre-
senting systemic clearance of d- and l-RA were assumed to be the
same as those of adult humans (Table 3). With volume of
distribution for RA enantiomers (VbodyC, L/kg) set to a value
of 0.693 L/kg equal to the total body water volume of the adult
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Figure 3. Plasma concentrations and urinary excretion data obtained after iv dosing of healthy adult men with MPH. Panel A: data
represent model simulated (lines) and observed (circles) plasma concentrations of d-MPH (N) and l-MPH (#) after iv dosing with 10 mg MPH (n = 13)
[4]; Panel B: data represent simulated (lines) and observed (triangles) urinary excretion of d-RA (m) and l-RA (D) after iv dosing with 10 mg MPH (n= 9)
[28]. Observed data were digitalized from graphs and are expressed as mean or mean 6 SD based on the ability to digitalize: this applies to all figure
legends unless otherwise specified.
doi:10.1371/journal.pone.0106101.g003
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Figure 4. Plasma concentrations obtained after oral dosing of healthy adults with MPH. Panel A: data represent model simulated (lines)
and observed (circles) plasma concentrations of d-MPH (N) and l-MPH (#) after oral dosing with 0.3 mg/kg MPH (n= 24) [29]; Panel B: Data as
described for Panel A obtained after oral dosing with 0.3 mg/kg MPH (n= 19) [30]; Panel C: Data as described for Panel A obtained after oral dosing
with 40 mg MPH (n= 21) [31].
doi:10.1371/journal.pone.0106101.g004
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monkey [80], model simulations of plasma RA concentrations in
adult monkeys (n = 4) following iv dosing of 0.3 mg/kg MPH
(NCTR data) were in line with collected kinetic data, except that
observations were under estimated at 0.02 h post dosing
(Figure 7B).
With hepatic metabolic constants established for intravenously
dosed adult monkeys, the gastric emptying first order constants for
d- and l-MPH (GEdC and GElC) were set to the value of 2.34 1/
h/kg20.25 [63] (Table 3). Use of oral uptake constants (K3dC and
K3lC, with a value of 1.293 1/h/kg0.25) and gut metabolism
parameters (K5dC and K5lC, with values of 0.042 and1.426 1/h/
kg0.75) derived from adult humans, the model captured MPH
plasma concentrations following oral dosing of 0.3 mg/kg MPH in
adult monkeys for the first two time points (0.25 and 0.5 h post-
dose), but overestimated for the remaining time points (Figure 7C).
To account for the reported greater intestinal expression and
activity of CES1 [75,86,87] and P450 enzymes [92] in cynomolgus
monkeys compared with humans, K5dC and K5lC values,
representing small intestinal metabolism, were visually increased
from adult human values of 0.042 and 1.426 1/h/kg0.75 to 1.05
and 35.64 1/h/kg0.75 to seek agreement with plasma levels of
MPH from 1 to 8 h following oral dosing of 0.3 mg/kg MPH in
adult monkeys (NCTR data). Using these calibrated model
parameters, model predictions in general captured the kinetic
Figure 5. Plasma concentrations obtained after oral dosing of healthy adult men with MPH. Panel A: data represent model simulated
(lines) and observed plasma concentrations of MPH (N) and RA (m) after oral dosing with 20 mg MPH (n = 5) [32]; Panel B: Data as described for Panel
A obtained after oral dosing with 20 mg MPH (n= 8) [33]; Panel C: Data as described for Panel A obtained after oral dosing with 0.3 mg/kg MPH
(n = 10) [24]; Panel D: Data as described for Panel A obtained after oral dosing with 0.15 mg/kg MPH (n= 5) [24].
doi:10.1371/journal.pone.0106101.g005
PBPK Model for Methylphenidate
PLOS ONE | www.plosone.org 14 September 2014 | Volume 9 | Issue 9 | e106101
PBPK Model for Methylphenidate
PLOS ONE | www.plosone.org 15 September 2014 | Volume 9 | Issue 9 | e106101
behavior of MPH for the first 4 h after dosing, with one plasma
sample contained non-quantifiable level of MPH at 4 h (Fig-
ure 7C). Model simulated plasma levels of MPH at 6 and 8 h post
dosing were slightly higher than the measured levels, with 1 of 4
plasma samples at 8 h containing non-quantifiable MPH level.
Using systemic distribution (VbodyC) and clearance parameters
(Ku_RAdC and Ku_RAlC) for RA enantiomers determined from
adult monkey iv dosing, simulations of plasma RA concentrations
somewhat overestimated experimental data in adult monkeys after
oral dosing of 0.3 mg/kg MPH (NCTR data) but maintained the
general profile of the time course for plasma RA levels
(Figure 7D).
Model Calibration: Young Monkeys
Scaling of adult monkey constants describing hepatic hydrolysis
(VmaxliverdC and VmaxliverlC) and oxidation (KmetdC and
KmetlC) largely overestimated plasma MPH and RA concentra-
tions in juvenile monkeys after a single intravenous dose of 3 mg/
kg MPH [24] (Figure 8). Simultaneous adjustment of these
parameters was undertaken to seek a better fit to plasma kinetics
for both MPH and RA in these juvenile monkeys [24], with
parameters describing systemic distribution (VbodyC) and clear-
ance (Ku_RAdC and Ku_RAlC) of RA enantiomers held to adult
monkey values (Table 3). With VmaxliverdC, VmaxliverlC,
KmetdC, and KmetlC values visually fitted to 350,000 mg/h/
kg0.75, 700,000 mg/h/kg0.75, 70 L/h/kg0.75 and 70 L/h/kg0.75,
respectively (Table 3), model predicted plasma MPH and RA
concentrations were in general agreement with reported data [24],
except for mild overestimations of MPH levels at 1.5, 2 and 3 h
within a factor of 2–3 (Figure 8).
Repeated oral dosing simulations with MPH (2.5 and 12.5 mg/
kg, twice with a 4 h interval/day, five days a week) in young
monkeys (n = 1–4 for each time point, NCTR data) were
conducted using model parameter values for hepatic metabolism
of MPH (VmaxliverdC, VmaxliverlC, KmetdC and KmetlC) and
systemic distribution (VbodyC) and clearance (Ku_RAdC and
Ku_RAlC) of RA derived from intravenous dosing of young
monkeys [24], and for MPH gastric emptying (GEdC and GElC)
and oral uptake (K3dC and K3lC) terms, set to adult monkey
values (Table 3). Metabolism of MPH in the gut was not
considered. Model predictions of plasma MPH and RA kinetics
were in general agreement with observations for both low dose
(2.5 mg/kg) and high dose (12.5 mg/kg) groups (Figures 9A–D)
with a few exceptions: the model somewhat underestimated MPH
levels within 1 h post dosing for the 12.5 mg/kg dose group except
for Monday (Figure 9C) and overpredicted plasma RA levels at
4 h after dosing for both 2.5 and 12.5 mg/kg dose groups
(Figures 9B and 9D). No apparent difference was noted for plasma
MPH and RA kinetics collected periodically over the course of two
years (Figure S1, Figure S2, Figure S3, and Figure S4).
Model Evaluation: Adult Humans
The calibrated adult human oral model was first evaluated
against plasma d-MPH concentration time course data collected in
healthy adults administered a single oral dose of 50 and 90 mg
MPH [34], a dose level slightly higher than the doses (20–40 mg)
used for model calibration (Table S1). The calibrated model
provided a good prediction of plasma d-MPH kinetic behaviors,
except that plasma d-MPH concentrations were slightly overesti-
mated at 12 h within a factor of 2–3 for both dose groups
(Figure 10A). Plasma d-MPH concentration time course data were
also obtained from healthy adults given two repeated oral doses of
30 mg MPH, 6 h apart [35] (Table S1). The kinetic behavior of d-
MPH over a period of 36 h was very well captured by the model
(Figure 10B).
Figures 10C and 10D show model predictions and observations
of plasma MPH concentrations in health adults administered a
single oral dose of 20 mg MPH [36] and three repeated oral doses
of 5 mg MPH taken 4 h apart [37], for which the time course of
plasma RA concentration was also reported (Table S1). Model
predictions of MPH plasma concentrations were adequate for both
studies, except for a slight overestimation within a factor of 3–4
noticed at last time points for both studies (at 10 h for [36] and at
30 h for [37]). Model predictions of RA plasma concentrations
were in excellent agreement with observed data [37].
The calibrated model was also tested against published urinary
excretion data with oral MPH [20,28] (Table S1). As shown in
Figure 11A, the model accurately replicated the time course of
urinary RA excretion over a period of 72 h after oral adminis-
tration of 20 mg MPH in healthy men [20]. Urinary excretion
time course for d- and l-RA over a period of 16 h following oral
administration of 40 mg MPH in healthy men [28] was slightly
overestimated within a factor of 1.5 (Figure 11B).
Figure 6. Plasma concentrations obtained after oral dosing of boys with MPH. Panel A: Data represent model simulated (lines) and
observed (circles) plasma concentrations of d-MPH (N) and l-MPH (#) after oral dosing with10 mg MPH in boys with ADHD (n= 9) [7]; Panel B: Data
as described for Panel A obtained after oral dosing with 10 mg MPH in boys with ADD (n= 5) [46]. Thin lines depict model simulations with MPH-
specific model parameters set to adult values, and thick lines represent model predictions of plasma l-MPH concentrations with the calibrated
children oral model, for which the value of K5lC describing gut metabolism of l-MPH was decreased from the adult value of 1.426 to 0.1 1/h/kg0.75,
while other MPH-specific model parameters were set to adult values.
doi:10.1371/journal.pone.0106101.g006
Table 4. Observed and simulated serum RA concentrations in boys after oral administration of MPH.
Patient No. Dose (mg/kg) Time (h) RA concentration (mg/L)
Observed Simulated
1 0.64 2.0 275 413
2 0.47 1.5 315 261
3 0.37 1.1 250 150
4 0.29 2.25 285 203
5 0.25 2.5 165 178
doi:10.1371/journal.pone.0106101.t004
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In addition, the calibrated adult human oral model was further
evaluated against other published kinetic studies with MPH in
healthy adults [38–43] (Table S1). With a few exceptions, the
calibrated adult human model generally predicted plasma
concentration time courses of MPH and RA collected in these
single- and multiple-dose studies (Figure S5 and Figure S6).
Model Evaluation: Children
The calibrated children oral model was first tested against
plasma d-MPH concentration time course data collected in
children [49,50] (Table S2). Figures 12A–D show model predic-
tions and observations of plasma d-MPH concentrations over a
period of 6 h in pre-school and school aged children administered
a single oral dose of 2.5–10 mg MPH [49]. Time courses of
Figure 7. Plasma concentrations obtained after iv and oral dosing of adult monkeys with MPH (NCTR data). Panel A: Data represent
model simulated (line) and observed (circles) individual plasma concentrations of MPH (N) after iv dosing with 0.3 mg/kg MPH (n = 4). One plasma
sample at 6 h and two other plasma samples at 24 h contained non-quantifiable levels of MPH (0.1 mg/L limit of quantification, LOQ) [52]; Panel B:
Data represent model simulated (line) and observed (triangles) individual plasma concentrations of RA (m) after iv dosing with 0.3 mg/kg MPH (n= 4);
Panel C: Data as described for Panel A obtained after oral dosing with 0.3 mg/kg MPH (n= 4). One plasma sample at 4 h and one plasma samples at
8 h contained non-quantitable levels of MPH [52]; Panel D: Data as described for Panel B obtained after oral dosing with 0.3 mg/kg MPH (n= 4).
Dashed lines represent model predictions using kinetic model parameters derived from the adult human oral model, whereas solid lines depict model
predictions using the calibrated adult monkey oral model, for which gut metabolism constants (K5dC and K5lC) were increased from adult human
values of 0.042 and 1.426 1/h/kg0.75 to 1.05 and 35.65 1/h/kg0.75 for d-MPH and l-MPH.
doi:10.1371/journal.pone.0106101.g007
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plasma d-MPH concentrations were very well predicted across the
dose range for both age groups, with the noted exception of school
children treated with 2.5 mg of MPH (Figure 12A), for whom the
measured plasma d-MPH levels were somewhat overestimated.
Plasma d-MPH concentration time course data were also obtained
in boys given a single oral dose of MPH at 5, 10 and 20 mg [50].
Model simulations in general agreed well with collected plasma d-
MPH kinetic data over a period of 10 h for three groups, except
that the model underestimated observations at 0.5 and 1 h for the
10 mg dose group but overestimated experimental data at 10 h for
the 5 mg dose group within a factor of 2–4 (Figure 12E).
The calibrated children oral model was also evaluated against
published data on plasma MPH concentrations collected in
children after oral MPH administration [47,48,51] (Table S2).
Single-dose kinetics of MPH in plasma was obtained in boys with
ADD over a period of 7 h following oral administration of 0.342
and 0.651 mg/kg MPH [47]. Model simulations accurately
tracked collected data (Figure 13A). Repeated-dose kinetics of
MPH in plasma was obtained in children administered three
repeated doses of 5–15 mg MPH taken 4 h apart, for which
plasma MPH concentrations were normalized to a dose of 5 mg
[48]. Simulation of plasma MPH kinetics over a period of 12 h
was in excellent agreement with observed data (Figure 13B). In
addition, the study of [51] also presented plasma MPH kinetic
data following repeated oral dose of MPH at 10–40 mg taken 4 h
apart, for which plasma MPH concentrations were normalized to
a dose of 20 mg. Observations were in good agreement with
model predictions, except that the simulated plasma levels of MPH
were somewhat higher than measured levels for the later time
points (from 8 to 24 h) (Figure 13C).
Model Evaluation: Juvenile Monkeys
Figure 14 shows model predictions and observations of MPH
plasma concentrations in juvenile male rhesus monkeys repeatedly
administered 10.7 (8.89–13.1) mg/kg or 16.5 (15.5–18.7) mg/kg of
MPH, twice daily, 3 h apart (at 9:00 and 12:00) [27]. When using
the calibrated young monkey oral model, model predictions of
MPH plasma concentrations collected one hour after oral dosing,
at 10:00 and 13:00, were in general agreement with observations
(Figure 14).
Assessment of Model Prediction Performance
Model prediction performance of plasma MPH or d- and l-
MPH levels was assessed using RMSE for data sets in children
reported by [7,46–51] and for data sets in juvenile monkeys
reported in this paper (NCTR data) and from Johns Hopkins
University [27].
The RMSE values for data sets used for children oral model
calibration [7,46] ranged from 0.3 to 2.0, with a mean of 1.0. The
calibrated model demonstrated similar performance when tested
against other data sets [47–51], yielding RMSE values ranged
from 1.11–4.88, with a mean of 2.4, of which, the RMSE value
(24.85) estimated for the study of [51] was excluded as an outlier.
The RMSE values for data sets used for juvenile monkey oral
Figure 8. Plasma concentrations obtained after iv dosing of juvenile monkeys with MPH. Data represent model simulated (thin lines for
MPH and thick lines for RA) and observed plasma concentrations of MPH (N) and RA (m) after iv dosing with 3 mg/kg MPH (n= 5) [24]. Dashed lines
represent model simulations using hepatic metabolic constants derived from the adult monkey iv model, whereas solid lines depict model
predictions using the calibrated juvenile monkey iv model, for which maximum metabolic constants (VmaxliverdC and VmaxliverlC) describing
hepatic hydrolysis and clearance terms describing hepatic oxidation (KmetdC and KmetlC) for d-MPH and l-MPH were increased from adult values of
38,000 mg/h/kg0.75, 90,000 mg/h/kg0.75, 0.7 L/h/kg0.75, and 0.7 L/h/kg0.75 to 350,000 mg/h/kg0.75, 700,000 mg/h/kg0.75, 70 L/h/kg0.75, and 70 L/h/kg0.75,
respectively.
doi:10.1371/journal.pone.0106101.g008
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Figure 9. Plasma concentrations obtained after repeated oral dosing of juvenile male monkeys with MPH (NCTR data). Panel A: Data
denote representative model simulated (lines) and observed (circles) individual plasma concentrations of MPH (N) after repeated oral dosing with
2.5 mg/kg MPH (n= 1–4 at each time point); Panel B: Data depict representative model simulated (lines) and observed (circles) individual plasma
concentrations of RA (N) after repeated oral dosing with 2.5 mg/kg MPH (n= 1–4 at each time point). Measurements of plasma RA concentrations at
pre-dose (approximately within 30 min of dosing) were combined with those at 24 h from previous dose; Panel C: Data as described for Panel A
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model calibration (NCTR data) ranged from 3.4 to 6.0, with a
mean of 4.1 for the 2.5 mg/kg dose group; and for the 12.5 mg/
kg dose group, ranged from 16–106, with a mean of 61.5. Similar
prediction performance as the high dose group (12.5 mg/kg) was
observed for juvenile monkey oral data sets (10.7 and 16.5 mg/kg)
from Johns Hopkins University [27] used for model evaluation,
obtained after oral dosing with 12.5 mg/kg MPH (n = 1–4 at each time point); Panel D: Data as described for Panel B obtained after oral dosing with
12.5 mg/kg MPH (n= 1–4 at each time point). MPH was administered twice a day, 4 h apart, five days a week (Monday to Friday) and kinetic studies
were performed from Monday to Thursday. Kinetic profiles of MPH and RA for each individual monkey were followed on the same day of the week
when quarterly blood sampling occurred over a 1 year period. On the day of blood collection, MPH was administered only once in the morning.
doi:10.1371/journal.pone.0106101.g009
Figure 10. Plasma concentrations obtained after oral dosing of healthy adult humans with MPH. Panel A: Data represent model
simulated (solid line, 90 mg MPH and dashed line, 50 mg MPH) and observed (circles) plasma concentrations of d-MPH after oral dosing with 90 mg
(N) and 50 mg(#) MPH (n= 49) [34]; Panel B: Data represent model simulated (line) and observed (circles) plasma concentrations of d-MPH (N) after
two repeated oral dosing with 30 mg/kg MPH, taken 6 h apart (n = 28) [35]; Panel C: Data represent model simulated (line) and observed (circles)
plasma concentrations (#, test formulation;N, reference formulation) of MPH after oral dosing with 20 mg MPH (n = 20) [36]; Panel D: Data represent
model simulated (line) and observed plasma concentrations of MPH (N) and RA (m) after three repeated oral dosing with 5 mg/kg MPH, taken 4 h
apart (n = 35) [37].
doi:10.1371/journal.pone.0106101.g010
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with average RMSE value of 31.5 (20–40), suggesting that the
model performs better for the low dose group (2.5 mg/kg) for the
juvenile monkey oral model. Comparable prediction performance
of the juvenile monkey oral model for the 2.5 mg/kg dose (mean
RMSE=4.1) and the children oral model (mean RMSE=2.1, for
data sets used for children oral model calibration and evaluation
[7,46–50]) provides confidence for interspecies extrapolation of
toxicity findings from the 2.5 mg/kg juvenile moneys dose group
to children.
Interspecies Extrapolation (Monkey to Human)
The developed PBPK model was utilized to derive oral HEDs
for boys 6 and 15 years of age to produce equivalent internal doses
for MPH associated with observed pubertal delays in juvenile
monkeys chronically exposed to 2.5 mg/kg MPH [26].
For juvenile male rhesus monkeys given repeated oral doses of
2.5 mg/kg MPH, model simulated peak concentration (Cmax)
and adjusted daily AUC for MPH at steady state were 10.4 ng/
mL and 50.3 ng/mL*h per day (Table S3). To achieve equivalent
Cmax at steady state as that in juvenile monkeys, model derived
HEDs in boys 6 and 15 years of age were 0.183 mg/kg (3.9 mg)
and 0.261 mg/kg (15.5 mg); and for the dosimetry of daily AUC,
0.084 mg/kg (1.8 mg) and 0.114 mg/kg (6.8 mg). These derived
HEDs (0.084–0.261 mg/kg) are below the recommended MPH
doses for children (0.3–0.8 mg/kg) by the American Academy of
Pediatrics.
Consistently, model estimated internal dose metrics (Cmax and
daily AUC) for boys either 6 or 15 years of age receiving
recommended MPH doses (0.3–0.8 mg/kg) [90] are greater than
those associated with observed pubertal delays in juvenile monkeys
(Table S3). Following repeated daily oral administration of
0.3 mg/kg MPH, model simulated Cmax and daily AUC at
steady state were 17.2 ng/mL and 180.4 ng/mL*h per day for
boys 6 years of age; and for boys 15 years of age, 12.0 ng/mL and
131.9 ng/mL*h per day. Following repeated oral administration
of 0.8 mg/kg MPH for a week, model simulated Cmax and daily
AUC were 45.8 ng/mL and 481.4 ng/mL*h per day for boys 6
years of age; and for boys 15 years of age, 31.9 ng/mL and
351.8 ng/mL*h per day.
Sensitivity Analysis
Table 5 presents model parameters determined to be sensitive
with absolute NSC values greater than 0.1 using the time course of
MPH plasma concentrations over a period of 24 h as the model
output. A similar sensitivity pattern was observed across species
and age, with some exceptions. For example, blood flows to the fat
and the slowly perfused tissues (QFC and QSC) were found to be
sensitive for monkeys, but not for humans. In addition, parameters
responsible for the hepatic hydrolysis of l-MPH (Kmliverl and
VmaxliverlC) were sensitive for young humans and monkeys, but
not for adults. Of note, some parameters, e.g. cardiac output
(QCC) and hepatic hydrolysis of d-MPH (Kmliverd and
Vmaxliverd), appear to impact the plasma concentrations of
MPH to a greater extent with absolute NSC values larger than 1.
With the exception of kinetic parameters associated with l-MPH
found to be nonsensitive, the same sensitivity pattern was observed
Figure 11. Urinary excretion data obtained after oral dosing of healthy adult men with MPH. Panel A: Data represent model simulated
(line) and observed (circles) percentage of total dose excreted in urine as RA (N) after oral dosing with 20 mg MPH (n= 3) [20]; Panel B: Data represent
model simulated (line) and observed (triangles) urinary excretion time courses of d-RA (m) and l-RA (D) after oral dosing with 40 mg MPH (n= 9) [28].
doi:10.1371/journal.pone.0106101.g011
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with regards to the time course of plasma d-MPH concentrations
over a period of 24 h. This is consistent with the finding that
plasma concentrations of l-MPH were negligible and plasma
concentrations of the d-enantiomer approximated those of the
racemic MPH.
Figure 12. Plasma concentrations obtained after oral dosing of children with MPH. Panel A: Data represent model simulated (lines) and
observed (circles) plasma concentrations of d-MPH after oral dosing with 2.5 mg MPH in preschool-aged (N) (n = 1) and school-aged (#) (n = 2)
children with ADHD [49]. Solid line represents simulations for preschool-aged children and dashed line represents simulations for school-aged
children; Panel B: Data as described for Panel A obtained after oral dosing with 5 mg MPH in preschool-aged (N) (n = 8) and school-aged (#) (n = 2)
children [49]; Panel C: Data as described for Panel A obtained after oral dosing with 7.5 mg MPH in preschool-aged (N) (n = 4) and school-aged (#)
(n = 1) children [49]; Panel D: Data as described for Panel A obtained after oral dosing with 10 mg MPH in preschool-aged (N) (n = 1) and school-aged
(#) (n = 4) children [49]; Panel E: Data represent model simulated (lines) and observed plasma concentration of d-MPH after oral dosing with 5 mg
(6), 10 mg (#), and 20 mg (N) MPH in boys with ADHD (n= 31) [50].
doi:10.1371/journal.pone.0106101.g012
Figure 13. Plasma concentrations obtained after oral dosing of children with MPH. Panel A: Data represent model simulated (dashed line,
0.6 mg/kg; solid line, 0.3 mg/kg) and observed (circles) plasma concentration of MPH after oral dosing with 0.6 mg/kg (#) and 0.3 mg/kg (N) MPH in
boys with ADD (n= 14) [47]; Panel B: Data represent model simulated (line) and observed plasma concentrations (#, fasting, N, normal) of MPH
normalized to a dose of 5 mg after three repeated oral dosing with 5–15 mg MPH, taken 4 h apart, in children with ADHD (n = 14) [48]; Panel C: Data
represent model simulated individual (lines) and observed (circles) plasma concentrations of MPH (N) normalized to a dose of 20 mg after two
repeated dosing with 10–40 mg MPH, taken 4 h apart, in children with ADHD (n= 14) [51].
doi:10.1371/journal.pone.0106101.g013
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Discussion
A PBPK model was constructed for the first time to describe the
kinetic behavior of MPH and its primary metabolite RA in young
and adult humans and non-human primates. The availability of
plasma concentration time courses of d- and l-MPH [4,29–31] and
urinary excretion profiles of d- and l-RA in adult humans [28],
coupled with the characterization of the hydrolysis of MPH
enantiomers using the recombinant human CES1A1 enzyme [16],
provide confidence in the appropriate estimation of enantiomer-
specific kinetic parameters for both MPH and RA. As a result, the
PBPK model was first calibrated in adult humans, and then
extrapolated to children and young and adult monkeys with
incorporation of potential species- and age-dependent differences
in MPH disposition.
With some exceptions, many model predictions are off by a
factor of 2–3 compared to experimental data. As recommended in
WHO PBPK guidance document [93], ‘‘In PBPK modelling,
predictions that are, on average, within a factor of 2 of the
experimental data have frequently been considered adequate.
When the training (or parameter estimation) data set and
evaluation data set are obtained in different experimental
animals/human subjects, as in most PBPK modelling activities,
the resulting simulations are not anticipated to fit the PK data
perfectly at all time points’’. Also, the evaluation of model value
should consider ‘‘biological basis and reliability of dose metric
predictions’’ in addition to ‘‘closeness to data’’. Hence, the
performance of the current MPH PBPK model is judged to be
adequate for practical application.
Model Development: Humans
To describe MPH hydrolysis in the liver, Michaelis affinity
constants, Kmliverd and Kmliverl, were from literature, while
VmaxliverdC and VmaxliverlC constants were determined by
Figure 14. Plasma concentrations obtained after repeated oral dosing of juvenile monkeys with MPH. Data represent model simulated
(lines) and observed (circles) individual plasma concentrations of MPH at 10:00 and 13:00 after daily oral dosing with either 10.7 mg/kg (lower line) or
16.5 mg/kg (upper line) MPH at 9:00 and 12:00 (n = 8) [27].
doi:10.1371/journal.pone.0106101.g014
Table 5. Sensitive model parameters.
Physiological Parameters Partition Coefficients Chemical specific model parameters
Adult
Humans
QCC, QLC, QRC, BW,VPC, VFC, VLC, VRC, VSC Pfat, Prich, Pslow, Pliver Kmliverd, VmaxliverdC, KmetdC, GEdC, K3dC, K5dC, GElC,
K3lC, K5lC
Children QCC, QLC, QRC,BW, VPC, VFC, VLC, VRC,
VSC, Age
Pfat, Prich, Pslow,
Pliver, Pbrain
Kmliverd, VmaxliverdC, KmetdC, GEdC, K3dC, K5dC,
GElC,K3lC, K5lC, Kmliverl, VmaxliverlC
Adult
Monkeys
QCC, QLC, QRC, QFC, QSC, BW, VPC, VLC,
VRC, VSC
Pfat, Prich, Pslow,
Pliver, Pbrain
Kmliverd, VmaxliverdC, KmetdC, GEdC, K3dC, K5dC, GElC,
K3lC, K5lC
Juvenile
Monkeys
QCC, QLC, QRC,QFC, QHC, QSC, BW, VPC,
VFC, VLC, VRC, VSC
Pfat, Prich, Pslow,
Pliver, Pbrain
Kmliverd, VmaxliverdC, KmetdC, GEdC, K3dC, GElC, K3lC,
Kmliverl,VmaxliverlC, KmetlC
Parameters with absolute NSC values greater than 1 are highlighted in bold.
doi:10.1371/journal.pone.0106101.t005
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parameter fitting. In vitro intrinsic liver clearance values,
calculated as Vmaxliver/Kmliver, for a 70 kg person, are
estimated to be 0.48 L/h/kg bw for d-MPH and 3.06 L/h/kg
bw for l-MPH. These values fall between those observed for
rapidly cleared drugs, e.g. deltamethrin (9.7 L/h/kg bw) [94] and
oseltamivir (8.4 L/h/kg bw) [95,96], which are also human
carboxylesterase I substrates, and the slowly cleared drug, e.g
amphetamine (0.004 L/h/kg bw) [97], which is structurally close
to MPH. Hence, it appears that parameter values for VmaxliverC
obtained by fitting the kinetic data are within the physiological
range. However, since many parameters required for a fully
mechanistic PBPK model are not available in literature and were
determined by parameter fitting, some of them may lack
physiological significance. To reduce the uncertainty and
strengthen the robustness of the model, additional studies are
needed to estimate model parameters.
With hepatic metabolic parameters derived from intravenous
dosing of adult humans [4], describing kinetic behaviors of MPH
following oral administration [24,29–33] became a challenge. The
model consistently overestimated plasma MPH levels after oral
administration, even with a low oral uptake constant. To account
for the relatively low plasma concentrations of MPH observed in
orally dosed adult humans, we hypothesized that pre-systemic
metabolism of MPH also occurred in the small intestine, via both
hydrolytic [73–75] and oxidative [76] metabolic pathways.
However, further studies are needed to better understand the fate
of MPH in the GI tract and to more reasonably estimate related
model parameters. MPH emptied from the stomach into the small
intestine lumen was assumed to be available immediately within
enterocytes, where MPH was either taken up into the portal blood
circulation or metabolized. The calibrated adult human model for
MPH suggested that approximately 85% of MPH administered
orally is metabolized in the small intestine of adult humans, with
the remaining taken up into the liver.
For children, another issue arose. The lack of iv dosing data
made it difficult for reasonable estimation of kinetic model
parameters because oral route of administration confounds the
kinetic interpretations. Thus, the calibrated adult human oral
model was extrapolated to describe the plasma kinetics of orally
administered MPH in children. Scaling of constants describing
hepatic and gut metabolism as well as oral uptake of MPH,
determined by optimization in adult humans, provided a sufficient
description of plasma d-MPH levels in children. However,
recalibration of the gut metabolism constant for l-MPH (K5lC,
1/h/kg0.75) was needed to accurately track the kinetic behavior of
l-MPH in children. The adult value of K5lC was decreased by
13 fold to account for the slower systemic clearance of l-MPH in
children. Plasma RA concentrations in children [19] were
predicted using scaled adult urinary excretion (clearance) con-
stants.
Sensitivity analysis indicated that model parameters represent-
ing hepatic and intestinal metabolism of MPH appeared to
significantly impact model predictions of plasma MPH concen-
trations in humans, both adults and children. To obtain more
reasonable estimates of these parameter values, studies using
in vitro preparations are needed to fully investigate the age-
dependent metabolism of MPH enantiomers (d- and l-MPH) in
the liver and the small intestine. With these new data, it may be
possible to derive a scaling approach to describe the maturation of
liver and gut metabolism of MPH. Additionally, in the current
model, the resultant metabolite RA was assumed to be taken up
immediately into the systemic circulation, and hence the rate of
RA formation after oral administration equals the rate of MPH
hydrolysis in the liver and the small intestine. Research is
necessary to examine the transport mechanisms of RA in the
liver and the small intestine. Also, pharmacokinetic studies in
children following iv administration of MPH with simultaneous
quantification of MPH and RA enantiomers would be of critical
importance for reasonable characterization of hepatic metabolism
of MPH and systemic clearance of RA in children.
Model Development: Monkeys
For monkeys, no in vitro metabolism studies were available for
the derivation of hepatic metabolic constants and those limited
kinetic studies from NCTR and Wargin et al. [24] have been
restricted to non-enantiospecific analytic approaches (i.e. reporting
only pooled d- and l-MPH concentrations). Further, the metab-
olism and excretion pathways of MPH have not been well
described in monkeys. The determination of enantiomer-specific
model parameters for monkeys became challenging. As such, the
development of the monkey MPH PBPK model relied primarily
on interspecies and intraspecies extrapolation using allometric
scaling, with new pharmacokinetic data collected at NCTR and
from Wargin et al. [24] as the primary sources for model
calibration.
The scaled model parameters describing hepatic metabolism of
d- and l-MPH calibrated in adult humans by iv administration in
general predicted plasma kinetics of d- and l-MPH in adult
monkeys after iv dosing. Correspondingly, scaling of adult human
urinary excretion (clearance) constants described plasma d- and l-
RA kinetics for adult monkeys. However, when extrapolating the
adult human oral model to adult monkeys, recalibration of gut
metabolism constants for d- and l-MPH was needed to account for
the potential greater gut metabolic capacity in monkeys than
humans [75,86,87,92]. With MPH-specific model parameters
recalibrated for adult monkeys after oral dosing, the scaled
constants describing systemic excretion of d- and l-RA from adult
humans worked well for the prediction of plasma d- and l-RA
kinetics for adult monkeys.
Next, the calibrated adult monkey iv and oral models were
extrapolated to describe the plasma kinetics of MPH in juvenile
monkeys given iv and oral doses. However, these intraspecies
extrapolations were not successful and recalibration was needed.
For iv dosing, plasma MPH is cleared more rapidly in young
monkeys [24] compared to adult monkeys (NCTR data) and
larger hepatic metabolic constants for d- and l-MPH were
required. Scaled hepatic hydrolysis terms (Vmaxliverd and
Vmaxliverl) and hepatic oxidation terms (Kmetd and Kmetl) are
estimated to be 9.9E5 mg/h, 2.0E6mg/h, 198 L/h and 198 L/h for
juvenile monkeys of 2.5 years old [24]; while for adult monkeys,
these values are estimated to be 2.1E5 mg/h, 4.9E5 mg/h, 3.83L/h,
and 3.83 L/h, respectively. In addition, model simulations
suggested that in young monkeys microsomal oxidation represents
a major route (approximately 68%) for MPH metabolism, similar
to those reported for rats and dogs [18,21]; while in adult
monkeys, the administered dose is thought to be predominantly
metabolized by hydrolysis (approximately 80%), similar to what is
found in humans [18]. With these MPH-specific model param-
eters recalibrated, scaling of adult monkey urinary excretion
constants for RA worked well for the description of plasma RA
kinetics after iv dosing in juvenile monkeys.
For oral dosing in juvenile monkeys, with hepatic metabolic
constants recalibrated from the juvenile monkey iv data [24],
scaling of adult monkey oral uptake constants for d- and l-MPH
worked well for the prediction of plasma d- and l-MPH kinetics in
juvenile monkeys. However no gut metabolism was assumed.
Subsequently, plasma d- and l-RA kinetics in juvenile monkeys
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after oral dosing was successfully described using scaled systemic
clearance terms for d- and l-RA determined in adult monkeys.
Due to lack of knowledge, the calibration of the monkey MPH
model is an exploratory evaluation of MPH pharmacokinetics in
monkeys. The metabolic pathways of MPH and systemic
clearance of RA in monkeys were assumed to be similar to those
identified in humans, and model parameter values were primarily
fit for purpose but without adequate empirical evidence. This is a
major concern of the current model. As such, there is more
uncertainty with regard to the estimation of model parameters for
the monkey model compared with the human model. To address
these uncertainties, further research using both in vitro and
in vivo systems is needed to determine if monkeys and humans
process MPH in a similar fashion and to provide evidence for
reasonable determination of kinetic model parameter values in
monkeys. Also, similar to humans, more studies need to be
conducted to explore the effect of age on the metabolism and
excretion of intravenously and orally dosed MPH in monkeys. In
addition, sensitivity analysis suggested that model outputs were
also sensitive to physiological parameters, e.g. cardiac output
(QCC), blood flow to the liver (QLC), and tissue volumes of the
liver and plasma (VLC and VPC). However, such physiological
information is not available for young monkeys, which were set to
adult monkey values in the current model. Characterization of
physiological parameters for young monkeys is required to
strengthen the model.
Model Improvement
In addition to the issues discussed above that need to be
addressed to increase model prediction performance, the current
model can be further improved in the following respects.
First, although immediate-release MPH has been established as
the ‘‘gold standard’’ for the treatment of ADHD, with the rapid
introduction of novel extended-release MPH dosage forms into the
market, it is of clinical relevance to also describe the pharmaco-
kinetic behaviors of extended-release MPH formulations. Com-
pared with immediate-release MPH, which is rapidly absorbed
from the intestine, the extended absorption profile of extended-
release MPH dosage forms are primarily controlled by pro-
grammed dissolution and release kinetics [12]. By taking into
account the characteristics of the extended-release formulations
and their interactions with the gastrointestinal tract, the current
model can be expanded to describe the pharmacokinetics of
extended-release MPH formulations.
Second, the advances in the understanding of pharmacological
[42] and toxicological mechanisms underlying the action of MPH
offer the possibility of incorporating the mechanistic component
(pharmacodynamic, PD) into the current PBPK model. The
establishment of the PBPK/PD model will allow for simultaneous
estimation of the internal dose metrics and associated biological
effects of MPH, and may provide insights into the causes of
individual variability in response to MPH treatment from both
pharmacokinetic and pharmacodynamic perspectives.
Third, large interpatient variability has been reported for
pharmacokinetics and clinical response of MPH and dosage must
be titrated for optimal effects [57,98]. With the incorporation of
statistical simulation techniques (i.e. Monte Carlo simulations) to
account for the probability distribution of physiological and
biochemical characteristics, the PBPK/PD model can better
address such large interindividual differences. In addition,
pharmacogenetic studies have reported the impact of polymor-
phisms of MPH targets (catecholamine candidate genes) [99] on
individual MPH-responses. Also, ethnic differences have been
observed for the hCES1 enzyme [100] and functional polymor-
phisms (mutations) of the hCES1 gene with reduced enzyme
activity have been identified [101,102]. Further efforts can be
made to develop a mechanistic covariate model by integrating
polymorphism into the PBPK/PD model, which can provide clues
for individualized MPH regimens based on genetic information.
Fourth, in the current model, plasma dose metrics of MPH were
employed for species extrapolation. Though kinetics of MPH in
plasma and tissues (e.g. heart and brain) were generally in parallel,
as shown in rats [58–60], dose metrics of target tissues might be
more representative of risk. However, although a direct effect of
MPH on the testis or an indirect effect at a site or sites in the
pituitary or hypothalamus has been implicated [26], the under-
lying mechanisms associated with MPH induced changes in
testosterone levels have not yet been unraveled. In addition,
though MPH metabolites are pharmacologically inactive, with the
exception of p-hydroxymethylphenidate [17,18], to our best
knowledge, no studies have been conducted to evaluate the
toxicity of MPH metabolites. Hence, further research is required
to identify the exact cellular and molecular processes involved in
the potential toxicity caused by MPH. Identified target tissues and
the mechanisms involved can be integrated into our PBPK model,
allowing a more accurate extrapolation of MPH effects across
species and age.
Other confounding issues also need further study. Some studies
reported that food may affect the absorption of either immediate-
release or extended-release MPH [39], while others did not [103].
Also sexual dimorphism in MPH pharmacokinetics has been
reported: women appear to require larger mg/kg doses to achieve
the same MPH plasma concentration as men, which might be
attributed to the more extensive first pass metabolism of MPH in
women [12,104]. However such a sex difference was not noticed
for children with ADHD [98]. With further studies performed to
verify the impact of food and sex on the disposition of MPH,
related kinetic parameters might be adjusted to account for such
effects.
Interspecies Extrapolation
With the incorporation of known variations in physiological
factors between experimental animals and humans, PBPK model
based interspecies extrapolation has become a useful tool to
quantitatively evaluate internal doses of a chemical or a drug
across species. The success of default scaling cross species seems
age- and route- dependent. Scaling of the adult human model
parameters to adult monkeys works well for predicting MPH
pharmacokinetics after intravenous dosing; while for oral dosing,
recalibration of gut metabolism constants derived from the adult
human oral model is needed. Contrarily, if extrapolating the
children oral model to juvenile monkeys, both hepatic and gut
metabolism constants need to be recalibrated. The necessity to
recalibrate model parameters obtained by default scaling for
interspecies extrapolation implies latent cross species variations in
the pharmacokinetics of MPH.
To better understand the disposition of MPH across species and
age, daily AUC values of MPH at steady state following repeated
daily oral dosing of MPH at 0.3 mg/kg, twice a day with 4 h apart,
were assessed for juvenile and adult monkeys and humans.
Consistent with the finding that juvenile monkeys require larger
oral MPH doses to achieve similar serum levels of MPH in adult
monkeys and humans as well as children [22,23,26,27], the daily
AUC value (7.9 ng/mL*h per day) of MPH in juvenile monkeys is
far below those in adult monkeys (25.1 ng/mL*h per day), adult
humans (107.1 ng/mL*h per day), and boys of 6 (179.2 ng/mL*h
per day) and 15 (130.6 ng/mL*h per day) years old. Juvenile
monkeys appear to metabolize MPH more rapidly than adult
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monkeys and humans as well as children, which is accounted for by
using larger hepatic metabolic constants for juvenile monkeys in the
model. The lower systemic exposure of MPH in adult monkeys
compared with adult humans and children could be explained by
the potential greater extent of first-pass metabolism occurred in the
gut of adult monkeys [75,86,87]. In addition, children were found to
have higher internal dose metrics compared with adult humans: the
most likely explanation might be that children have lower gut
metabolism capacity for the l-MPH, as assumed in the model.
Next, PBPK model based interspecies extrapolation was
employed for human risk assessment of MPH. Due to the
limitations for direct evaluation of the toxicity of environmental
chemicals or drugs in humans, species extrapolation of toxicity
data from experimental animals has been commonly used to
predict responses in humans despite differences may exist in how
humans and experimental animals respond to chemicals. In the
current model, with the observed pubertal delay in young monkeys
administered 2.5 mg/kg MPH as the endpoint of interest, model
derived HEDs (0.183 mg/kg and 0.261 mg/kg for boys 6 and 15
years of age using Cmax as the dosimetry; and 0.084 and
0.114 mg/kg for daily AUC dosimetry) are below the recom-
mended MPH doses for children (0.3–0.8 mg/kg) by the
American Academy of Pediatrics. Of note, consistent with the
finding that chronic MPH exposure resulted in temporary
intervention of serum testosterone concentrations in juvenile male
rhesus monkeys [26,27], higher salivary testosterone levels and
atypically flat circadian rhythms in salivary testosterone have been
reported in children receiving MPH [25]. Since the impairment of
pubertal development noticed in monkeys was only transitory, the
concerns about the clinical use of MPH in pre-pubescent children
may be somewhat relieved. However, given the widespread use of
MPH and related amphetamines in the pediatric population, more
studies in both animal models and humans need to be conducted
to fully describe the effects of MPH, particularly those associated
with chronic treatment.
Supporting Information
Figure S1 Plasma concentrations obtained after repeat-
ed oral dosing of juvenile male monkeys with MPH
(NCTR data). Data represent model simulated (lines) and
observed (circles) individual plasma concentrations of MPH (N)
after repeated oral dosing with 2.5 mg/kg MPH (n=1–4 at each
time point) across the study. MPH was administered twice a day,
five days a week (Monday to Friday) and kinetic studies were
performed from Monday to Thursday. On the day of blood
collection, MPH was administered only once in the morning (solid
lines). Dashed lines represent plasma concentration time courses of
MPH and RA under repeated dosing schedules.
(TIF)
Figure S2 Plasma concentrations obtained after repeat-
ed oral dosing of juvenile male monkeys with MPH
(NCTR data). Data represent model simulated (lines) and
observed (circles) individual plasma concentrations of RA (N) after
repeated oral dosing with 2.5 mg/kg MPH (n= 1–4 at each time
point) across the study. Measurements of plasma RA concentra-
tions at pre-dose (approximately within 30 min of dosing) were
combined with those at 24 h from previous dose. MPH was
administered twice a day, five days a week (Monday to Friday) and
kinetic studies were performed from Monday to Thursday. On the
day of blood collection, MPH was administered only once in the
morning (solid lines). Dashed lines represent plasma concentration
time courses of MPH and RA under repeated dosing schedules.
(TIF)
Figure S3 Plasma concentrations obtained after repeat-
ed oral dosing of juvenile male monkeys with MPH
(NCTR data). Data represent model simulated (lines) and
observed (circles) individual plasma concentrations of MPH (N)
after repeated oral dosing with 12.5 mg/kg MPH (n= 1–4 at each
time point) across the study. MPH was administered twice a day,
five days a week (Monday to Friday) and kinetic studies were
performed from Monday to Thursday. On the day of blood
collection, MPH was administered only once in the morning (solid
lines). Dashed lines represent plasma concentration time courses of
MPH and RA under repeated dosing schedules.
(TIF)
Figure S4 Plasma concentrations obtained after re-
peated oral dosing of juvenile male monkeys with MPH
(NCTR data). Data represent model simulated (lines) and
observed (circles) individual plasma concentrations of RA (N) after
repeated oral dosing with 12.5 mg/kg MPH (n= 1–4 at each
time point) across the study. Measurements of plasma RA
concentrations at pre-dose (approximately within 30 min of
dosing) were combined with those at 24 h from previous dose.
MPH was administered twice a day, five days a week (Monday to
Friday) and kinetic studies were performed from Monday to
Thursday. On the day of blood collection, MPH was adminis-
tered only once in the morning (solid lines). Dashed lines
represent plasma concentration time courses of MPH and RA
under repeated dosing schedules.
(TIF)
Figure S5 Plasma concentrations obtained after oral
dosing of healthy adult humans with MPH. Panel A: Data
represent model simulated (lines) and observed individual (circles)
plasma concentrations of d-MPH after oral dosing with 20 mg
MPH (n= 4) [40]; Panel B: Data represent model simulated (line)
and observed (circles) plasma concentrations of MPH after two
repeated dosing with 10 mg MPH, taken 5 h apart (n = 18) [43];
Panel C: Data represent model simulated (line) and observed
(circles) plasma concentrations of d-MPH after oral dosing with
40 mg of MPH (n= 24) [39]; Panel D: Data as described for Panel
A obtained after oral dosing with 40 mg MPH (n= 6) [42]; Panel
E: Data represent model simulated (lines) and observed plasma
concentrations of d-MPH (N) and d-RA(m) after oral dosing with
20 mg d-MPH (n= 15) [41].
(TIF)
Figure S6 Plasma concentrations obtained after oral
dosing of adult humans with MPH. Panel A: Data represent
model simulated (lines) and observed plasma concentrations of d-
MPH (N), l-MPH (#), d-RA (m) and l-RA(D) after oral dosing with
10 mg MPH (n= 1) [38]; Panel B: Data as described for Panel A
obtained after oral dosing with 20 mg MPH (n=1) [38]; Panel C:
Data as described for Panel A obtained after oral dosing with
30 mg MPH (n= 1) [38]; Panel D: Data as described for Panel A
obtained after oral dosing with 40 mg.
(TIF)
Table S1 Immediate release MPH pharmacokinetic
studies used for model calibration and evaluation for
healthy adult male and female humans.
(DOC)
Table S2 Immediate release MPH pharmacokinetic
studies used for model calibration and evaluation for
male and female children with ADHD and ADD.
(DOC)
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Table S3 Human equivalent dose (HED) calculations
for MPH in boys either 6 or 15 years of age based on
juvenile male rhesus monkey toxicity and pharmacoki-
netic studies with MPH. For juvenile monkeys, experimental
daily AUC was calculated as total AUC over one week divided by
5 days and adjusted daily AUC used for HED calculations was
calculated as total AUC over one week divided by 7 days; for boys,
daily AUC was calculated as (total AUC over one week 2 total
AUC from Money to Wednesday) divided by 4 days.
(DOC)
Text S1 Additional pharmacokinetic studies in humans.
(DOC)
Text S2 Methylphenidate PBPK model code.
(TXT)
Text S3 PBPK model code for physiological parameter
estimation in children.
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